Bifogade filer
Prenumeration
Kalender
Est. tid* | ||
2026-02-12 | 08:00 | Bokslutskommuniké 2025 |
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-07-07 | N/A | X-dag ordinarie utdelning ATORX 0.00 SEK |
2025-07-05 | N/A | Årsstämma |
2025-04-24 | - | Kvartalsrapport 2025-Q1 |
2025-04-07 | - | Split ATORX 1000:1 |
2025-03-27 | - | Extra Bolagsstämma 2024 |
2025-01-22 | - | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-07-11 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2024-05-07 | - | Årsstämma |
2024-05-06 | - | Kvartalsrapport 2024-Q1 |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-07-13 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | Årsstämma |
2023-05-04 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2023-04-25 | - | Kvartalsrapport 2023-Q1 |
2023-04-14 | - | Extra Bolagsstämma 2022 |
2023-02-10 | - | Bokslutskommuniké 2022 |
2022-10-20 | - | Kvartalsrapport 2022-Q3 |
2022-07-12 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-04-27 | - | Kvartalsrapport 2022-Q1 |
2022-02-11 | - | Bokslutskommuniké 2021 |
2021-11-08 | - | Extra Bolagsstämma 2021 |
2021-10-21 | - | Kvartalsrapport 2021-Q3 |
2021-07-13 | - | Kvartalsrapport 2021-Q2 |
2021-06-01 | - | Årsstämma |
2021-05-03 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2021-04-27 | - | Kvartalsrapport 2021-Q1 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-10-22 | - | Kvartalsrapport 2020-Q3 |
2020-07-13 | - | Kvartalsrapport 2020-Q2 |
2020-05-06 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2020-05-05 | - | Årsstämma |
2020-04-23 | - | Kvartalsrapport 2020-Q1 |
2020-02-12 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-07-11 | - | Kvartalsrapport 2019-Q2 |
2019-05-10 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2019-05-09 | - | Årsstämma |
2019-04-17 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-10-26 | - | Kvartalsrapport 2018-Q3 |
2018-07-12 | - | Kvartalsrapport 2018-Q2 |
2018-04-27 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2018-04-26 | - | Årsstämma |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-03 | - | X-dag ordinarie utdelning ATORX 0.00 SEK |
2017-05-02 | - | Årsstämma |
2017-05-02 | - | Kvartalsrapport 2017-Q1 |
2017-02-17 | - | Bokslutskommuniké 2016 |
2016-11-14 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Alligator Bioscience AB (publ) today announces an update to its dividend policy following the constitution of Alligator’s new Board of Directors on 7 May 2025.
The updated dividend policy reads as follows:
Alligator will continue to focus on further developing its project portfolio and pursue partnerships for, or the sale of, its projects. Should Alligator receive significant proceeds from such events, the Board’s intention is to propose that the proceeds, save for any funds deemed necessary for working capital and activities deemed value enhancing for all shareholders, will be distributed to the shareholders of Alligator in the form of a dividend or repurchase of shares. In its proposal, the Board will consider Alligator’s strategy, objectives and third-party commitments in force at any given time, as well as applicable limitations in the Swedish Companies Act.
“The updated dividend policy reflects our sharpened strategic and operational focus, aimed at enabling the continued development and partnering of mitazalimab. Thus, the policy ensures that the capital structure is fully aligned with our long-term priorities,” said Hans-Peter Ostler, Chairman of the Board.
For further information, please contact:
Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00
Johan Giléus, CFO
E-mail: johan.gileus@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00
The information was submitted for publication, through the agency of the contact person set out above, at 10:45 a.m. CEST on 8 May 2025.
About Alligator Bioscience
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company’s lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.
Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.